阿霉素磁性蛋白微球靶向治疗胃癌的实验研究及临床应用  

Experiment and clinical application of targeting treatment with adriamycin magnetic albumin microspheres in human gastric carcinoma

作　　者：陶凯雄[1,2,3] 陈道达[1,2,3] 王国斌[1,2,3] 白植军 芦晓明[1,2,3] 田元 吴在德[1,2,3] 虎凤仙 聂秀[1,2,3] 

机构地区：[1]同济医科大学协和医院普外科 [2]同济医院普外科 [3]公共卫生学院

出　　处：《中华外科杂志》1999年第4期205-207,I013,共4页Chinese Journal of Surgery

基　　金："九五"国家重点医学科技攻关专题资助

摘　　要：目的探讨阿霉素磁性微球联合外磁场的靶向疗法在动物体内的药代动力学特点以及对进展期胃癌的辅助性化疗作用。方法（１）选择１３０只大鼠检测阿霉素磁性微球靶向给药后动物体内靶区组织药物浓度。（２）采取人胃液２０～１００ｍｌ，检测阿霉素磁性微球在人类胃液中的稳定性。（３）将此微球靶向应用于５５例进展期胃癌患者术前辅助化疗以观察其临床及病理组织学疗效。结果靶向给药２小时后动物体内靶区组织药物浓度即达峰值，且长时间维持在高水平；阿霉素磁性微球在人类不同ｐＨ值胃液中能保持稳定性；该靶向疗法可改善患者症状，提高肿瘤切除率及术后生存率，增加肿瘤组织的病理学疗效（Ｐ＜００１）。结论阿霉素磁性微球经消化道给药联合外磁场在动物及人体内具有良好的靶向定位作用，作为进展期胃癌的术前辅助性化疗具有一定的临床应用价值。Objective To study the pharmacokinetics in experimental animals and observe the concurrent anticancer effects in human advanced gastric cancer as an adjuvant chemotherapy, when adriamycin magnetic albumin microspheres (ADM MAM) were combined with external static magnetic fields. Methods The drug concentration of targeting tissues in the animals and the stability of ADM MAM in human gastric juices were determined. Clinical and histopathological changes were observed in 55 cases of advanced gastric carcinomas after targeting treatment. Results The peak concentrations of the targeting tissue were highest after ADM MAMs were administered for 2 hours and remained at the high level for a long time. ADM MAM maintained its stability in human gastric juices. Targeting treatment improved the patients′ symptoms, raised the rated of tumor resection, prolonged patients′ lifetime, and enhanced histopathological effects ( P <0 01). Conclusions The administration of ADM MAM combined with the external static magnetic fields is effective for targeting location and is of clinical value as a preoperative adjuvant chemotherapy for human advanced gastric carcinoma.

关 键 词：胃肿瘤 阿霉素 磁性蛋白微球 辅助疗法 

分 类 号：R735.205[医药卫生—肿瘤] R979.14[医药卫生—临床医学]